Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Citius Pharmaceuticals Inc (CTXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,970
  • Shares Outstanding, K 10,670
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,380 K
  • 36-Month Beta 4.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +48.56%
on 06/28/18
3.12 -0.96%
on 07/13/18
+0.43 (+16.17%)
since 06/13/18
3-Month
2.08 +48.56%
on 06/28/18
3.12 -0.96%
on 07/13/18
+0.09 (+3.00%)
since 04/13/18
52-Week
2.08 +48.56%
on 06/28/18
6.27 -50.72%
on 07/19/17
-3.16 (-50.56%)
since 07/13/17

Most Recent Stories

More News
Citius Announces Key Addition to its Scientific Advisory Board

Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Dr. Lawrence Mermel has accepted a position on the Citius Scientific Advisory Board....

CTXR : 3.09 (+5.46%)
Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the...

CTXR : 3.09 (+5.46%)
Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark

Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office....

CTXR : 3.09 (+5.46%)
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements...

CTXR : 3.09 (+5.46%)
Citius Reports Progress in Hemorroid Treatment Program

Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic...

CTXR : 3.09 (+5.46%)
Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias

Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, published the proceedings of a...

CTXR : 3.09 (+5.46%)
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it will be presenting at the BIO...

CTXR : 3.09 (+5.46%)
Citius Pharma Sets Crosshairs on Billion Dollar Opportunity in Catheter-Related Bloodstream Infections

SANTA MONICA, CA / ACCESSWIRE / January 10, 2018 / Central venous catheters (CVCs) are a critical component of healthcare, with about seven million CVCs used every year to supply medicines, nutrients,...

CTXR : 3.09 (+5.46%)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

PALM BEACH, Florida, November 7, 2017 /PRNewswire/ --

CARA : 21.72 (-0.50%)
CTXR : 3.09 (+5.46%)
ONCS : 1.30 (unch)
TXMD : 6.68 (-0.74%)
VBLT : 2.15 (unch)
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs

Commitment to bring new drug developments to the market through highly regarded and respected clinical research and studies are of a continued result of ongoing collaborations with academic and medical...

CARA : 21.72 (-0.50%)
CTXR : 3.09 (+5.46%)
ONCS : 1.30 (unch)
VBLT : 2.15 (unch)
TXMD : 6.68 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CTXR with:

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 3.24
1st Resistance Point 3.17
Last Price 3.09
1st Support Level 2.97
2nd Support Level 2.84

See More

52-Week High 6.27
Fibonacci 61.8% 4.67
Fibonacci 50% 4.18
Fibonacci 38.2% 3.68
Last Price 3.09
52-Week Low 2.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar